Technical Analysis for AZN - Astrazeneca PLC

Grade Last Price % Change Price Change
grade C 43.8 -2.82% -1.27
AZN closed down 2.82 percent on Friday, February 28, 2020, on 1.98 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical AZN trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Gilligan's Island Buy Setup Bullish Swing Setup 0.00%
Doji - Bullish? Reversal 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Expansion Breakdown Bearish Swing Setup -2.82%
200 DMA Support Bullish -2.82%
Lower Bollinger Band Walk Weakness -2.82%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics; and a strategic collaboration with FibroGen, Inc. to develop and commercialize FG-4592, a compound for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.
Cancer Drugs Antibodies Monoclonal Antibodies Infection Neuroscience Breast Cancer Schizophrenia Asthma Chronic Kidney Disease Heart Failure Hypertension Psychoactive Drugs Anemia Astrazeneca End Stage Renal Disease Autoimmune And Inflammatory Diseases Pulmonology Chronic Condition Angina Bipolar Disorder Chronic Obstructive Pulmonary Diseases Major Depressive Disorders Respiratory Disease Södertälje Municipality Bipolar Disorders Ironwood Pharmaceuticals

Is AZN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 51.55
52 Week Low 36.8323
Average Volume 2,845,261
200-Day Moving Average 45.08
50-Day Moving Average 49.39
20-Day Moving Average 48.51
10-Day Moving Average 47.65
Average True Range 1.15
ADX 20.0
+DI 15.86
-DI 53.90
Chandelier Exit (Long, 3 ATRs ) 46.79
Chandelier Exit (Short, 3 ATRs ) 46.42
Upper Bollinger Band 51.74
Lower Bollinger Band 45.28
Percent B (%b) -0.23
BandWidth 13.33
MACD Line -0.96
MACD Signal Line -0.44
MACD Histogram -0.5247
Fundamentals Value
Market Cap 110.91 Billion
Num Shares 2.53 Billion
EPS 1.52
Price-to-Earnings (P/E) Ratio 28.82
Price-to-Sales 3.91
Price-to-Book 6.22
PEG Ratio 2.37
Dividend 0.90
Dividend Yield 2.05%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.47
Resistance 3 (R3) 45.37 44.72 45.19
Resistance 2 (R2) 44.72 44.30 44.77 45.09
Resistance 1 (R1) 44.26 44.03 44.49 44.36 45.00
Pivot Point 43.61 43.61 43.73 43.66 43.61
Support 1 (S1) 43.15 43.19 43.38 43.25 42.60
Support 2 (S2) 42.50 42.92 42.55 42.51
Support 3 (S3) 42.04 42.50 42.41
Support 4 (S4) 42.14